Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Predictors Of Patient Reported Outcomes And Cost Of Care In Younger Men With Newly Diagnosed Prostate Cancer
UroToday.com - In the online version of The Prostate, Dr. Ravishankar Jayadevappa and colleagues from the University of Pennsylvania analyzed the association between race, risk of biochemical recurrence and recovery pattern of patient reported outcomes such as satisfaction with care, HRQoL (generic and prostate-specific) and cost in younger men with newly diagnosed prostate cancer (CaP). The investigators hypothesized that younger African American men will have impaired HRQoL outcomes and will present with higher cost compared to younger Caucasian CaP patients.
generic viagra online
NCDP Health Care Reform Recommendations Advocate For Diabetes Prevention, Treatment And Care
The National Changing Diabetes((R)) Program (NCDP), a program of Novo Nordisk, and several member associations today urged President Obama and members of Congress to make the prevention, detection and treatment of diabetes, one of the nation"s most pervasive and costly diseases, a priority in reforming the U.S. healthcare system.
News of the day
Do Electronic Health Records Help Or Hinder Medical Education?
Many countries worldwide are digitizing patients" medical records. In the
Public Health

Medivation Selects ProTrials To Conduct International Phase III Clinical Trials

ProTrials Research, Inc.TM, a leader in the clinical research organization industry, announced Medivation, Inc. (NASDAQ:MDVN) has chosen the company to conduct separate international Phase III clinical trials for two novel treatments. ProTrials will test MDV3100 for treating prostate cancer and the investigational drug Dimebon TM as a treatment for Huntington"s disease. Due to the complex nature of these Phase III trials, Medivation again selected ProTrials as its contract research organization partner because of ProTrials" successful past performance with the company"s Phase I, II and III trials. "We are working with ProTrials specifically because of its people and their long track records of conducting clinical trials," noted Lynn Seely, M.D., chief medical officer at Medivation. "While many CROs have research managers that are industry veterans, it"s unusual to find a CRO offering such deep experience levels across the team." ProTrials will oversee the Huntington"s trial across the United States, Canada and Europe, and the United States and Canada for the prostate cancer trial. Both clinical trials are expansive in nature, involving hundreds of patients and about 125 test sites total. They will both be randomized and placebo-controlled. "Medivation"s repeated selection of ProTrials as a clinical trials partner is a nod to our track record of efficiency, cost effectiveness and most importantly, our GCP compliance in conducting clinical trials," said ProTrials CEO Jodi Andrews. "With prostate cancer being one of the most prevalent types of cancer in men, and Huntington"s disease having no treatments currently approved by the U.S. Food and Drug Administration, these Phase III clinical trials are crucial for moving potentially life-saving treatments to market." Visitors to the upcoming 2009 American Society for Clinical Oncology (ASCO), being held May 29-June 2 at the Orange County Convention Center in Orlando, FL, can learn more about ProTrials in booth #703. ProTrials will also be attending the 45th Annual Meeting of the Drug Information Association (DIA), being held June 21-25 at the San Diego (CA) Convention Center, and will be in booth #1215. ProTrials Research, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009